Dual ESMO readouts could expand Lynparza's reach to new patients

In a pair of wins for Lynparza, new data presented at ESMO showed the PARP inhibitor led to survival benefits in both a biomarker-selected group of prostate cancer patients and a combination with Avastin to treat ovarian cancer in a first-line maintenance setting.

Lynparza is one of several PARPs that sponsors are developing in new indications beyond BRCA-mutant cancers (see "Broadening the PARP Playing Field")...